Table 1.

Settings for use of a rheumatoid arthritis flare measure4.

Clinical Trials
Detecting adequacy of dose/regimen for duration of therapeutic effect — driving to remission (“tight control”)
Aiding dose/regimen optimization — titration and tapering while maintaining remission
Assessing effect of concomitant medications to control oscillating symptoms/signs
Assessing and reporting of episodic disease-worsening as an adverse event
Determining remission as absence of disease flare among other measures
Clinical Practice
Facilitating MD-patient communication when considering change in therapy for intermittent disease-worsening
Determining need to change treatment
Assessing patient-specific interventions to control episodic worsening
Enabling assessments to apply “tight control” strategies on an individual patient basis
Assessing episodic disease-worsening
Limiting effect of and disability associated with periodic disease-worsening (e.g., time lost from work)